1981
DOI: 10.1038/bjc.1981.232
|View full text |Cite
|
Sign up to set email alerts
|

Phenytoin-induced changes in the pharmacokinetics of misonidazole in radiotherapy patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

1
2
0

Year Published

1982
1982
2001
2001

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(3 citation statements)
references
References 13 publications
1
2
0
Order By: Relevance
“…Plasma elimination half-lives of misonidazole in our patients receiving anticonvulsant therapy ranged between 4.1 and 8.9 h with a mean value of 6.2 h, which was comparable with the half-life values between 5.4 and 7.9 h reported earlier in similar patients (Workman et al , 1980;Williams et al, 1983;Matheson et al, 1984). Metabolic induction of misonidazole could be important, as administration of phenytoin and phenobarbitone might be associated with a reduced neurotoxicity of misonidazole in man (Moore et al, 1981;Williams et al, 1983). In one of our patients with brain glioma (C19) without anticonvulsant therapy a plasma elimination half-life of misonidazole of 9.5 h was measured, which is in agreement with a mean half-life of 10-12 h normally found in patients not enzymically induced Workman et al , 1978).…”
Section: Discussionsupporting
confidence: 84%
See 1 more Smart Citation
“…Plasma elimination half-lives of misonidazole in our patients receiving anticonvulsant therapy ranged between 4.1 and 8.9 h with a mean value of 6.2 h, which was comparable with the half-life values between 5.4 and 7.9 h reported earlier in similar patients (Workman et al , 1980;Williams et al, 1983;Matheson et al, 1984). Metabolic induction of misonidazole could be important, as administration of phenytoin and phenobarbitone might be associated with a reduced neurotoxicity of misonidazole in man (Moore et al, 1981;Williams et al, 1983). In one of our patients with brain glioma (C19) without anticonvulsant therapy a plasma elimination half-life of misonidazole of 9.5 h was measured, which is in agreement with a mean half-life of 10-12 h normally found in patients not enzymically induced Workman et al , 1978).…”
Section: Discussionsupporting
confidence: 84%
“…C19 was higher than the mean value of 8.9 mg/1 in the group of patients receiving 1.3 g of misonidazole/m2. The plasma levels of desmethylmisonidazole in patients nos Cl-C5 receiving misonidazole in combination with anticonvulsant therapy have to be considered separately, since the liver microsomal-enzyme-inducing drugs phenobarbitone and phenytoin were proven to cause an increase of the plasma desmethylmisonidazole levels and a decrease of the plasma elimination half-life of misonidazole, while plasma misonidazole levels 3-4 h after intake remained unchanged (Workman et al , 1980;Moore et al , 1981;Williams et al , 1983). In our patients with anticonvulsant comedication plasma desmethylmisonidazole levels indeed were higher than those reported in patients without anticonvulsant medication (Notter et al , 1980).…”
Section: Discussionmentioning
confidence: 99%
“…Moore et al (6) studied the effects of diphenylhydantoin on the pharmacokinetics of MISO in patients and found that while the half-life of MISO was significantly reduced, peak plasma levels were unchanged. We found that 40 mg/kg of diphenylhydantoin reduced the half-life of MISO in rats (unpublished results).…”
Section: Discussionmentioning
confidence: 99%